Patents by Inventor Steven James Quimby

Steven James Quimby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BTK inhibitor compounds
    Patent number: 11542249
    Abstract: The invention provides BTK Inhibitor compounds of the formula pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: January 3, 2023
    Assignee: Eli Lilly and Company
    Inventors: Kenneth James Henry, Jr., Albert Khilevich, Steven Lee Kuklish, Katherine Marie Partridge, Steven James Quimby
  • BTK INHIBITOR COMPOUNDS
    Publication number: 20200290997
    Abstract: The invention provides BTK Inhibitor compounds, pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.
    Type: Application
    Filed: October 30, 2018
    Publication date: September 17, 2020
    Inventors: Kenneth James Henry, Jr., Albert Khilevich, Steven Lee Kuklish, Katherine Marie Partridge, Steven James Quimby
  • Opioid receptor antagonists
    Patent number: 8338611
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: December 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby
  • Opioid Receptor Antagonists
    Publication number: 20110105571
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: January 6, 2011
    Publication date: May 5, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • Opioid receptor antagonists
    Patent number: 7902372
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080269296
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z. A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 30, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080255152
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 16, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charies Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080207701
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: April 2, 2008
    Publication date: August 28, 2008
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • Diphenylether amide derivatives as opioid receptor antagonists
    Patent number: 7378448
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: May 27, 2008
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist
    Patent number: 6559171
    Abstract: The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: May 6, 2003
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby